Abstract:e15522 Background: colorectal cancer(CRC) is third in incidence and mortality in worldwide with a 5-year survival rate is 65%. CRC patients(pts) with active glucose metabolism have a worse outcome. Molecular biological mechanisms in this subgroup have not been well uncovered. Here we identified ACAA2 has a significant prognostic role in CRC pts and more down-regulated in those with higher standardized uptake value(SUV). Then we focused on its functions and mechanisms behind it. Methods: Clinical and transcriptional data of pts with CRC obtained from GSE39582 dataset (n = 510) and a Zhongsh an Hospital Fudan University Cohort(ZHFUC) with CRC diagnosed at 6/2015-12/2018 were collected (n = 441). The ACAA2 protein expression of ZHFUC was evaluated by immunohistochemistry staining. Metabolic activity was evaluated by SUV. Overall survival (OS) was analyzed via Kaplan-Meier Curves with Log-rank test and multivariable Cox regression. Silencing (KD) and over-expression (OE) of ACAA2 were performed in CRC cells, respectively(KD: HCT116;RKO and OE: DLD1;RKO). The effect of ACAA2 was tested through CCK8, colony formation assays, cell cycle assays, seahorse for glucose metabolism and subcutaneous xenograft models. The potential mechanism under ACAA2 contribution was explored by RNA sequencing and western blot. Results: ACAA2 of ZHFUC was down-regulated in CRC compared to normal tissues. Pts divided into ACAA2 high (n = 226) and low (n = 215) with an evenly distribution in their clinicopathological features.Of 143 pts with available PETCT imaging took as a SUV-related group), 78 were identified as ACAA2 high and 65 were low. In comparison to ACAA2 high ones, pts in ACAA2 low showed an higher SUV (p < 0.05) and a significantly worse OS (total pts: p = 0.012; SUV-related group:p = 0.024; median OS is not reached). The multivariate analysis showed that ACAA2 low was independently associated with inferior OS [total pts: HR 1.99(95%CI: 1.2 ¨C 3.2), p < 0.001; SUV-related group: HR 2.51(95%CI: 1.1 ¨C 5.7), p =< 0.05]. Over-expression ACAA2 inhibited tumor growth both in vitro and in vivo, and lower glucose metabolism and arrested G0/G1 cell cycle were observed in HCT116-OE cells, while reversed effects in RKO-KD cells. gene expression profiling analysis and consistent results in western blot highlighted the role of AKT signaling pathway in those contributions of ACAA2. A AKT inhibitor could suppress cell proliferation causing by silencing ACAA2 both in vitro and in vivo. Conclusions: while ACAA2 expression was an independent prognostic factor for CRC pts. And those of them with an active glucose metabolism had a lower ACAA2 expression. The silencing and over-expression of ACAA2 expression in CRC cell lines promoted and inhibited cell proliferation and tumor growth in vitro and in vivo, oppositely. ACAA2 expression levels might classified a subtype of CRC pts, who might benefit from AKT inhibitors treatment.

Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer

CCR7 High Expression Leads to Cetuximab Resistance by Cross-Talking with EGFR Pathway in PI3K/AKT Signals in Colorectal Cancer

Identification and Prognostic Analysis of the Cetuximab Resistance-Related Gene REV1 in RAS Wild-Type Metastatic Colorectal Cancer.

Identification of Key Genes Involved in Tumor Immune Cell Infiltration and Cetuximab Resistance in Colorectal Cancer

ACY1 Downregulation Enhances the Radiosensitivity of Cetuximab-Resistant Colorectal Cancer by Inactivating the Wnt/β-Catenin Signaling Pathway

The role of ACAA2 in colorectal caner patient with active glucose metabolism.

Predictive and Prognostic Implications of 4E-BP1, Beclin-1, and LC3 for Cetuximab Treatment Combined with Chemotherapy in Advanced Colorectal Cancer with Wild-Type KRAS: Analysis from Real-World Data

Autophagy-Related Proteins Beclin-1 And Lc3 Predict Cetuximab Efficacy In Advanced Colorectal Cancer

Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS

Survival Analysis of Cetuximab Combined with Chemotherapy for Advanced Colorectal Cancer and Effect of KRAS on Treatment

Molecular mechanisms of cetuximab resistance in metastatic colorectal cancer

Prediction of Target Genes and Pathways Associated with Cetuximab Insensitivity in Colorectal Cancer.

4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis

LncRNA UCA1 mediates Cetuximab resistance in Colorectal Cancer via the MiR-495 and HGF/c-MET Pathways

KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer.

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance

CAC1 Knockdown Reverses Drug Resistance Through the Downregulation of P-gp and MRP-1 Expression in Colorectal Cancer

FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer

Data from <i>KLF4</i> p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer